Search

Your search keyword '"Massone C"' showing total 574 results
Start Over Author "Massone C"
574 results on '"Massone C"'

1. Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas

Author

Caruso L, Castellino A, Dessì D, Flenghi L, Giordano A, Ibatici A, Massone C, Pileri A, Proietti I, Pupo L, Quaglino P, Rupoli S, and Zinzani PL

Subjects
cutaneous t- cell lymphoma, mycosis fungoides, sèzary sindrome, mogamulizumab, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Laura Caruso,1 Alessia Castellino,2 Daniela Dessì,3 Leonardo Flenghi,4 Antonio Giordano,5 Adalberto Ibatici,6 Cesare Massone,7 Alessandro Pileri,8 Ilaria Proietti,9 Livio Pupo,10 Pietro Quaglino,11 Serena Rupoli,12 Pier Luigi Zinzani13,14 1Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliero Universitaria Policlinico G. Rodolico - San Marco Di Catania, Catania, Italy; 2Department of Hematology, Santa Croce E Carle Hospital, Cuneo, Italy; 3Department of Hematology, Businco Hospital Arnas AOB, Cagliari, Italy; 4Hematology and Bone Marrow Transplantation Unit, Santa Maria Della Misericordia Hospital, Perugia, Italy; 5Department of Hematology, Fondazione Policlinico Universitario Agostino Gemelli—IRCCS, Rome, Italy; 6Hematology and Transplant Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; 7Dermatology Unit, Ospedali Galliera, Genova, Italy; 8Dermatology Unit, IRCCS S. Orsola-Malpighi Polyclinic, Bologna, Italy. Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), Alma Mater Studiorum University of Bologna, Bologna, Italy; 9Dermatology Unit”Daniele Innocenzi”, Department of Medical-Surgical Sciences and Bio-Technologies, Sapienza University of Rome, Terracina, Italy; 10UOC Lymphoproliferative Diseases, Fondazione PTV Policlinico Tor Vergata, Rome, Italy; 11Dermatologic Clinic, Department of Medical Sciences University of Turin Medical School, Turin, Italy; 12Clinic of Hematology, Ospedali Riuniti Ancona, Ancona, Italy; 13IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy; 14Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, ItalyCorrespondence: Pier Luigi Zinzani, IRCCS University Hospital of Bologna, Seràgnoli Institute of Hematology, and Department of Specialized, Diagnostic and Experimental Medicine, University of Bologna, via Massarenti 9, Bologna, 40138, Italy, Tel +39 051 2144042, Fax +39 051 2144037, Email pierluigi.zinzani@unibo.itAbstract: Mycosis fungoides and Sèzary syndrome are the most studied subtypes common cutaneous T-cell lymphomas. The current treatment objective is to improve the clinical manifestations of the disease in the affected areas, to relieve symptoms and to halt disease progression. Patients with early-stage mycosis fungoides are usually managed with skin-directed therapies, whereas patients with resistant or advanced-stage mycosis fungoides or Sèzary syndrome often require systemic drugs. Over the last decade, new drugs have been developed, increasing the breadth of treatment options for cutaneous T-cell lymphomas patients. Mogamulizumab is a first-in-class defucosylated humanized IgG1 κ monoclonal antibody, which exerts its anti-tumour action by selectively binding to C-C chemokine receptor 4 and increasing antibody-dependent cellular cytotoxicity activity against malignant T-cells. Several clinical trials showed that mogamulizumab is able to effectively control the cutaneous T-cell lymphomas in each site (skin, blood, lymph nodes and viscera), improving patients’ symptoms, function and overall quality of life with a manageable safety profile. In this report, we discuss 12 cases of patients with mycosis fungoides or Sèzary syndrome successfully treated with mogamulizumab in real-life clinical practice in Italy.Keywords: cutaneous T- cell lymphoma, mycosis fungoides, Sèzary syndrome, mogamulizumab

Published
2022

4. Hautmetastasen viszeraler Karzinome

Author

Massone, C., Fried, I., Requena, L., Cerroni, L., Cerroni, Lorenzo, editor, Garbe, Claus, editor, Metze, Dieter, editor, Kutzner, Heinz, editor, and Kerl, Helmut, editor

Published
2016
Full Text
View/download PDF

9. Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients

Author

Ciccarese, G., Dalmasso, B., Bruno, W., Queirolo, P., Pastorino, L., Andreotti, V., Spagnolo, F., Tanda, E., Ponti, G., Massone, C., Drago, F., Parodi, A., Ghigliotti, G., Pizzichetta, M. A., Ghiorzo, P., Ciccarese, G., Dalmasso, B., Bruno, W., Queirolo, P., Pastorino, L., Andreotti, V., Spagnolo, F., Tanda, E., Ponti, G., Massone, C., Drago, F., Parodi, A., Ghigliotti, G., Pizzichetta, M. A., and Ghiorzo, P.

Subjects
medicine.medical_specialty, Nevi and melanomas, Skin Neoplasms, lcsh:Medicine, Dermoscopy, Nodular melanoma, Melanocyte Inducing Transcription Factor, General Biochemistry, Genetics and Molecular Biology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, CDKN2A, Dysplastic nevi, medicine, Humans, Genetic Predisposition to Disease, Melanoma, neoplasms, Cancer genetics, Retrospective Studies, E318K, Microphthalmia-Associated Transcription Factor, Germline variant, integumentary system, business.industry, Nevi, Research, lcsh:R, Cutaneous melanoma, Renal cell carcinoma, Susceptibility, General Medicine, medicine.disease, Microphthalmia-associated transcription factor, Penetrance, Dermatology, body regions, Phenotype, 030220 oncology & carcinogenesis, Dysplastic nevus, Cancer genetic, business
Abstract

Background The p.E318K variant of the Melanocyte Inducing Transcription Factor (MITF) has been implicated in genetic predisposition to melanoma as an intermediate penetrance allele. However, the impact of this variant on clinico-phenotypic, as well as on dermoscopic patterns features of affected patients is not entirely defined. The purpose of our study was to assess the association between the p.E318K germline variant and clinic-phenotypical features of MITF+ compared to non-carriers (MITF−), including dermoscopic findings of melanomas and dysplastic nevi. Methods we retrospectively analyzed a consecutive series of 1386 patients recruited between 2000 and 2017 who underwent genetic testing for CDKN2A, CDK4, MC1R and MITF germline variants in our laboratory for diagnostic/research purposes. The patients were probands of melanoma-prone families and apparently sporadic single or multiple primary melanoma patients. For all, we collected clinical, pathological information and dermoscopic images of the histopathologically diagnosed melanomas and dysplastic nevi, when available. Results After excluding patients positive for CDKN2A/CDK4 pathogenic variants and those affected by non-cutaneous melanomas, our study cohort comprised 984 cutaneous melanoma patients, 22 MITF+ and 962 MITF−. MITF+ were more likely to develop dysplastic nevi and multiple primary melanomas. Nodular melanoma was more common in MITF+ patients (32% compared to 19% in MITF−). MITF+ patients showed more frequently dysplastic nevi and melanomas with uncommon dermoscopic patterns (unspecific), as opposed to MITF− patients, whose most prevalent pattern was the multicomponent. Conclusions MITF+ patients tend to develop melanomas and dysplastic nevi with histopathological features, frequency and dermoscopic patterns often different from those prevalent in MITF− patients. Our results emphasize the importance of melanoma prevention programs for MITF+ patients, including dermatologic surveillance with digital follow-up.

Published
2020

24. European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology

Author

Ioannides, D., primary, Vakirlis, E., additional, Kemeny, L., additional, Marinovic, B., additional, Massone, C., additional, Murphy, R., additional, Nast, A., additional, Ronnevig, J., additional, Ruzicka, T., additional, Cooper, S.M., additional, Trüeb, R.M., additional, Pujol Vallverdú, R.M., additional, Wolf, R., additional, and Neumann, M., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results